Detecting an Early Response to Donepezil With Measures of Visual Attention
Alzheimer Disease
About this trial
This is an interventional other trial for Alzheimer Disease focused on measuring Alzheimer Disease, Attention, Donepezil hydrochloride
Eligibility Criteria
Inclusion Criteria:
- Clinical diagnosis of Alzheimer's Disease
- Mini Mental State Examination score >15 / 30
- Can swallow pills
Exclusion Criteria:
- No other dementia due to Parkinson's disease, Lewy Body dementia, Normal Pressure Hydrocephalus, Fronto-temporal dementia, or prominent cerebral vascular accident
- No prior or concurrent use of cholinesterase inhibitors
- No prior or concurrent use of memantine hydrochloride
- No other concurrent anticholinergic treatments
Sites / Locations
- Winthrop-University Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Drug
Placebo
Participants in the Drug group received oral 5mg of Donepezil Hydrochloride daily for 6 months. The Drug group was assessed at baseline, after approximately 6 weeks and after 6 months of treatment. The baseline to 6 weeks phase was part of the double-blind, placebo controlled portion of the trial.
Participants in the placebo group first received oral administration of a placebo pill for approximately 6 weeks. After that initial interval, the study was unblinded and participants in the placebo group then received 5mg of donepezil hydrochloride treatment for 6 months. The Placebo group was evaluated at baseline, after 6 weeks of placebo, after 6 weeks of donepezil hydrochloride drug treatment, and 6 months of donepezil hydrochloride treatment.